Aadi Bioscience, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AADI research report →
Companyaadibio.com
Aadi Bioscience, Inc. , a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.
- CEO
- David J. Lennon
- IPO
- 2018
- Employees
- 53
- HQ
- Pacific Palisades, CA, US
Price Chart
Valuation
- Market Cap
- $94.89M
- P/E
- -2.52
- P/S
- 0.00
- P/B
- 2.51
- EV/EBITDA
- -1.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -79.63%
- ROIC
- -105.62%
Growth & Income
- Revenue
- $7.14M · -72.50%
- Net Income
- $-20,596,000 · 67.66%
- EPS
- $-0.03 · 98.59%
- Op Income
- $-114,400,000
- FCF YoY
- -60.10%
Performance & Tape
- 52W High
- $3.81
- 52W Low
- $1.21
- 50D MA
- $2.56
- 200D MA
- $2.16
- Beta
- 0.34
- Avg Volume
- 200.71K
Get TickerSpark's AI analysis on AADI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 4, 25 | Dalal Anupam | other | 1,561,000 |
| Mar 4, 25 | Castelein Caley | other | 1,666,000 |
| Mar 4, 25 | Zhao Baiteng | other | 1,250,000 |
| Mar 4, 25 | Dornan David | other | 687,979 |
| Mar 4, 25 | BALL BRYAN | other | 100,000 |
| Mar 1, 25 | BALL BRYAN | other | 5,000 |
| Mar 3, 25 | BALL BRYAN | sell | 2,147 |
| Mar 1, 25 | BALL BRYAN | other | 5,000 |
| Feb 28, 25 | Aghazadeh Behzad | other | 8,333,000 |
| Mar 1, 25 | Giacobello Scott M. | other | 6,750 |
Our AADI Coverage
We haven't published any research on AADI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AADI Report →